Associations - STK11 mutation

BIOMARKER:

STK11 mutation

Entrez ID:

6794

Related biomarkers:

‹

›

STK11 mutation STK11 mutation	Non Small Cell Lung Cancer NSCLC	nivolumab Resistant: B - Late Trials nivolumab Resistant : B
STK11 mutation STK11 mutation	Non Small Cell Lung Cancer NSCLC	DRP-104 Sensitive: B - Late Trials DRP-104 Sensitive : B
STK11 mutation STK11 mutation	Non Small Cell Lung Cancer NSCLC	durvalumab Resistant: B - Late Trials durvalumab Resistant : B
STK11 mutation STK11 mutation	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	docetaxel Resistant: C3 – Early Trials docetaxel Resistant : C3
STK11 mutation STK11 mutation	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	atezolizumab Resistant: C3 – Early Trials atezolizumab Resistant : C3
STK11 mutation STK11 mutation	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	rivoceranib + camrelizumab Sensitive: C3 – Early Trials rivoceranib + camrelizumab Sensitive : C3
STK11 mutation STK11 mutation	Non Small Cell Lung Cancer NSCLC	pembrolizumab Resistant: C3 – Early Trials pembrolizumab Resistant : C3
STK11 mutation STK11 mutation	Non Small Cell Lung Cancer NSCLC	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3
STK11 mutation STK11 mutation	Non Small Cell Lung Cancer NSCLC	PD-L1 inhibitor Sensitive: C3 – Early Trials PD-L1 inhibitor Sensitive : C3
STK11 mutation STK11 mutation	Non Small Cell Lung Cancer NSCLC	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
STK11 mutation STK11 mutation	Non Small Cell Lung Cancer NSCLC	cetuximab + avelumab Resistant: C3 – Early Trials cetuximab + avelumab Resistant : C3
STK11 mutation STK11 mutation	Lung Adenocarcinoma LUAD	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3
STK11 mutation STK11 mutation	Non Small Cell Lung Cancer NSCLC	atezolizumab Resistant: C3 – Early Trials atezolizumab Resistant : C3
STK11 mutation STK11 mutation	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	durvalumab + CP-675206 Resistant: C3 – Early Trials durvalumab + CP-675206 Resistant : C3
STK11 mutation STK11 mutation	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	durvalumab Resistant: C3 – Early Trials durvalumab Resistant : C3
STK11 mutation STK11 mutation	Pituitary Gland Carcinoma Pituitary Gland Carcinoma	temozolomide + capecitabine Resistant: C4 – Case Studies temozolomide + capecitabine Resistant : C4
STK11 mutation STK11 mutation	Pituitary Gland Carcinoma Pituitary Gland Carcinoma	everolimus Sensitive: C4 – Case Studies everolimus Sensitive : C4
STK11 mutation STK11 mutation	Pancreatic Cancer Pancreatic Cancer	everolimus Sensitive: C4 – Case Studies everolimus Sensitive : C4
STK11 mutation STK11 mutation	Lung Non-Small Cell Squamous Cancer Lung Non-Small Cell Squamous Cancer	pembrolizumab Resistant: C4 – Case Studies pembrolizumab Resistant : C4
STK11 mutation STK11 mutation	Lung Adenocarcinoma LUAD	abemaciclib Sensitive: C4 – Case Studies abemaciclib Sensitive : C4
STK11 mutation STK11 mutation	Non Small Cell Lung Cancer NSCLC	APG-115 Sensitive: D – Preclinical APG-115 Sensitive : D
STK11 mutation STK11 mutation	Lung Cancer Lung Cancer	dasatinib + selumetinib + RTB101 Sensitive: D – Preclinical dasatinib + selumetinib + RTB101 Sensitive : D
STK11 mutation STK11 mutation	Lung Cancer Lung Cancer	dasatinib Resistant: D – Preclinical dasatinib Resistant : D
STK11 mutation STK11 mutation	Non Small Cell Lung Cancer NSCLC	sirolimus Sensitive: D – Preclinical sirolimus Sensitive : D

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

ACCEPT COOKIES

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

ACCEPT COOKIES

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

ACCEPT COOKIES